Last reviewed · How we verify
AK104 IV infusion；Chiauranib oral
AK104 IV infusion；Chiauranib oral is a Tyrosine kinase inhibitor Small molecule drug developed by Akeso. It is currently in Phase 1 development for Non-small cell lung cancer, Renal cell carcinoma.
Tyrosine kinase inhibitor
Tyrosine kinase inhibitor Used for Non-small cell lung cancer, Renal cell carcinoma.
At a glance
| Generic name | AK104 IV infusion；Chiauranib oral |
|---|---|
| Sponsor | Akeso |
| Drug class | Tyrosine kinase inhibitor |
| Target | VEGFR, PDGFR, FGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Chiauranib is a potent and selective inhibitor of multiple receptor tyrosine kinases, including VEGFR, PDGFR, and FGFR.
Approved indications
- Non-small cell lung cancer
- Renal cell carcinoma
Common side effects
- Hypertension
- Diarrhea
- Fatigue
Key clinical trials
- A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK104 IV infusion；Chiauranib oral CI brief — competitive landscape report
- AK104 IV infusion；Chiauranib oral updates RSS · CI watch RSS
- Akeso portfolio CI
Frequently asked questions about AK104 IV infusion；Chiauranib oral
What is AK104 IV infusion；Chiauranib oral?
How does AK104 IV infusion；Chiauranib oral work?
What is AK104 IV infusion；Chiauranib oral used for?
Who makes AK104 IV infusion；Chiauranib oral?
What drug class is AK104 IV infusion；Chiauranib oral in?
What development phase is AK104 IV infusion；Chiauranib oral in?
What are the side effects of AK104 IV infusion；Chiauranib oral?
What does AK104 IV infusion；Chiauranib oral target?
Related
- Drug class: All Tyrosine kinase inhibitor drugs
- Target: All drugs targeting VEGFR, PDGFR, FGFR
- Manufacturer: Akeso — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Renal cell carcinoma
- Compare: AK104 IV infusion；Chiauranib oral vs similar drugs
- Pricing: AK104 IV infusion；Chiauranib oral cost, discount & access